The FDA has approved Novartis's Rhapsido, making it the first medicine for chronic friction hives.

NVS · Novartis AG

The AI's read

This gives Novartis a new approved use for Rhapsido and makes it the only prescription option for both friction-triggered and spontaneous chronic hives. More patients had full hive clearance than with a placebo, though fewer than 1 in 3 taking it had full clearance at 12 weeks. Use is limited to adults whose symptoms persist despite antihistamines. Novartis also reported positive late-stage trial results in relapsing multiple sclerosis, adding another favorable company development.